Favorable outcomes in patients with high donor-derived T cell count after in vivo T cell-depleted reduced-intensity allogeneic stem cell transplantation.
Publication/Presentation Date
5-1-2012
Abstract
Patients with hematologic malignancies were conditioned using a rabbit antithymocyte globulin-based reduced-intensity conditioning regimen for allogeneic stem cell transplantation. Donor-derived CD3(+) cell count (ddCD3), a product of CD3(+) cell chimerism and absolute CD3(+) cell count, when <110/μL at 8 weeks post-stem cell transplantation predicted a high risk of sustained mixed chimerism and relapse. Alternatively, patients with a higher ddCD3 developed graft-versus-host disease more frequently, and when partially chimeric, had higher rates of conversion to full donor chimerism after withdrawal of immunosuppression. Early data from our small cohort of patients indicate that ddCD3 at 8 weeks may be used to guide decisions regarding withdrawal of immunosuppression and administration of donor lymphocyte infusion in partially T cell-depleted reduced-intensity regimens.
Volume
18
Issue
5
First Page
794
Last Page
804
ISSN
1523-6536
Published In/Presented At
Toor, A. A., Sabo, R. T., Chung, H. M., Roberts, C., Manjili, R. H., Song, S., Williams, D. C., Jr, Edmiston, W., Gatesman, M. L., Edwards, R. W., Ferreira-Gonzalez, A., Clark, W. B., Neale, M. C., McCarty, J. M., & Manjili, M. H. (2012). Favorable outcomes in patients with high donor-derived T cell count after in vivo T cell-depleted reduced-intensity allogeneic stem cell transplantation. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 18(5), 794–804. https://doi.org/10.1016/j.bbmt.2011.10.011
Disciplines
Medicine and Health Sciences
PubMedID
22005648
Department(s)
Department of Medicine, Hematology-Medical Oncology Division
Document Type
Article